Search Results - "BONI, Joseph P"

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer by HIDALGO, Manuel, BUCKNER, Jan C, ERLICHMAN, Charles, POLLACK, Marilyn S, BENI, Joseph P, DUKART, Gary, MARSHALL, Bonnie, SPEICHER, Lisa, MOORE, Laurence, ROWINSKY, Eric K

“…Purpose: Patients with advanced cancer received temsirolimus (Torisel, CCI-779), a novel inhibitor of mammalian target of rapamycin, i.v. once daily for 5 days…”
Get full text

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma by ATKINS, Michael B, HIDALGO, Manuel, DUKART, Gary, SHERMAN, Matthew L, STADLER, Walter M, LOGAN, Theodore F, DUTCHER, Janice P, HUDES, Gary R, PARK, Young, LIOU, Song-Heng, MARSHALL, Bonnie, BONI, Joseph P

“…To evaluate the efficacy, safety, and pharmacokinetics of multiple doses of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with…”
Get full text

Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors by SPUNT, Sheri L, GRUPP, Stephan A, GILBERTSON, Richard J, VIK, Terry A, SANTANA, Victor M, GREENBLATT, David J, CLANCY, Jill, BERKENBLIT, Anna, KRYGOWSKI, Mizue, ANANTHAKRISHNAN, Revathi, BONI, Joseph P

“…To determine dose-limiting toxicities, maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of weekly intravenous temsirolimus, a mammalian…”
Get full text

Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma by MOTZER, Robert J, HUDES, Gary R, DUTCHER, Janice P, CURTI, Brendan D, MCDERMOTT, David F, ESCUDIER, Bernard J, NEGRIER, Sylvie, DUCLOS, Brigitte, MOORE, Laurence, O'TOOLE, Timothy, BONI, Joseph P

“…Temsirolimus, an inhibitor of the mammalian target of rapamycin, has single-agent activity against advanced renal cell carcinoma (RCC). A recommended dose and…”
Get full text

Phase I Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors by ERLICHMAN, Charles, HIDALGO, Manuel, BONI, Joseph P, MARTINS, Patricia, QUINN, Susan E, ZACHARCHUK, Charles, AMORUSI, Peter, ADJEI, Alex A, ROWINSKY, Eric K

“…The maximum tolerated dose (MTD) and the dose-limiting toxicities of EKB-569, a selective, irreversible inhibitor of the epidermal growth factor receptor…”
Get full text

Exposure–response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma by Toukam, Marie, Boni, Joseph P., Hamadani, Mehdi, Caimi, Paolo F., Cruz, Hans G., Wuerthner, Jens

“…Purpose To investigate camidanlumab tesirine (Cami) exposure–response (E–R) relationships, using an integrated population pharmacokinetic model, for patients…”
Get full text

Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma by Toukam, Marie, Wuerthner, Jens, Havenith, Karin, Hamadani, Mehdi, Caimi, Paolo F., Kopotsha, Tim, Cruz, Hans G., Boni, Joseph P.

“…Purpose The objective of this analysis was to develop a population pharmacokinetic (PPK) model to characterize camidanlumab tesirine (Cami) pharmacokinetics…”
Get full text

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma by Geoerger, Birgit, Kieran, Mark W, Grupp, Stephan, Perek, Danuta, Clancy, Jill, Krygowski, Mizue, Ananthakrishnan, Revathi, Boni, Joseph P, Berkenblit, Anna, Spunt, Sheri L

“…Abstract Purpose A phase II study of temsirolimus was conducted in children and adolescents with high-grade glioma, neuroblastoma or rhabdomyosarcoma. Patients…”
Get full text

Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications by Danesi, Romano, Boni, Joseph P, Ravaud, Alain

“…Abstract Identification of the role of biological pathways in metastatic renal cell carcinoma (mRCC) has led to the development of targeted agents for its…”
Get full text

Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc‐concentration modelling by Hibma, Jennifer E., Kantarjian, Hagop M., DeAngelo, Daniel J., Boni, Joseph P.

“…Aim The aim of this study was to characterize the effect of inotuzumab ozogamicin on QT interval in patients with B‐cell malignancies. Methods Data were pooled…”
Get full text

Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing Considerations by Boni, Joseph P, Hug, Bruce, Leister, Cathie, Sonnichsen, Daryl

“…Temsirolimus, a highly specific inhibitor of mammalian target of rapamycin (mTOR), is a novel anticancer targeted therapy with a new mechanism of action. The…”
Get full text

A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults by Boni, Joseph P., Leister, Cathie, Hug, Bruce, Burns, Jaime, Sonnichsen, Daryl

“…Purpose Temsirolimus, a selective inhibitor of mammalian target of rapamycin, is an approved treatment for patients with advanced renal cell carcinoma (RCC)…”
Get full text

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer by Buckner, Jan C., Forouzesh, Bahram, Erlichman, Charles, Hidalgo, Manuel, Boni, Joseph P., Dukart, Gary, Berkenblit, Anna, Rowinsky, Eric K.

“…Summary An oral formulation of temsirolimus (Torisel®), an inhibitor of the mammalian target of rapamycin, was evaluated on an intermittent schedule (once…”
Get full text

Population Pharmacokinetics of CCI-779: Correlations to Safety and Pharmacogenomic Responses in Patients with Advanced Renal Cancer by Boni, Joseph P., Leister, Cathie, Bender, Gregor, Fitzpatrick, Virginia, Twine, Natalie, Stover, Jennifer, Dorner, Andrew, Immermann, Fred, Burczynski, Michael E.

“…Objective Our objective was to estimate the pharmacokinetic parameters of CCI‐779 and its metabolite, sirolimus, and evaluate associations of exposure…”
Get full text

Effects of age and gender on the pharmacokinetics of bromfenac in healthy volunteers by Boni, J P, DeCleene, S A, Cevallos, W H, Hicks, D R, Korth-Bradley, J M

“…To compare the pharmacokinetic parameters of bromfenac, a nonsteroidal antiinflammatory drug under development, in healthy volunteers of various ages and…”
Get more information

ABCL-367 Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined With Mosunetuzumab and Glofitamab Helps Guide Dosing for Patients With DLBCL by Li, Yuezhe, Wilkins, A. Katharina, Knab, Timothy, Keir, Chris, Boni, Joseph P.

“…Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]) is an antibody–drug conjugate comprising an anti-CD19 antibody conjugated to a…”
Get full text

Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined With Mosunetuzumab and Glofitamab Helps Guide Dosing for Patients With DLBCL by Li, Yuezhe, Katharina Wilkins, A., Knab, Timothy, Keir, Chris, Boni, Joseph P.

Get full text

ABCL-366 Quantitative Systems Pharmacology Model Predicts Combination Activity of CD19-Targeted Loncastuximab Tesirine Co-Dosed With a CD20/CD3 T-Cell Bispecific (Epcoritamab) in Diffuse Large B-Cell Lymphoma by Li, Yuezhe, Wilkins, A. Katharina, Davis, Jimena, Knab, Timothy, Keir, Chris, Boni, Joseph P.

“…Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]) is an antibody–drug conjugate comprising an anti-CD19 antibody conjugated to a…”
Get full text

Quantitative Systems Pharmacology Model Predicts Combination Activity of CD19-Targeted Loncastuximab Tesirine Co-Dosed With a CD20/CD3 T-Cell Bispecific (Epcoritamab) in Diffuse Large B-Cell Lymphoma by Li, Yuezhe, Katharina Wilkins, A., Davis, Jimena, Knab, Timothy, Keir, Chris, Boni, Joseph P.

Get full text

Abstract 875: Quantitative systems pharmacology modeling of loncastuximab tesirine combined with mosunetuzumab and glofitamab helps guide dosing for patients with DLBCL by Li, Yuezhe, Wilkins, A Katharina, Knab, Tim, Boni, Joseph P.

“…Abstract Introduction: CD19 and CD20, B-lymphocyte surface antigens, are clinically validated therapeutic targets for the treatment of B-cell malignancies…”
Get full text